MR 2266

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534666

CAS#: 56649-76-4

Description: MR 2266 is a narcotic antagonist.

Chemical Structure

img
MR 2266
CAS# 56649-76-4
Instruction

Theoretical Analysis

MedKoo Cat#: 534666
Name: MR 2266
CAS#: 56649-76-4
Chemical Formula: C21H27NO2
Exact Mass: 325.20
Molecular Weight: 325.452
Elemental Analysis: C, 77.50; H, 8.36; N, 4.30; O, 9.83

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MR 2266; MR-2266; MR2266

IUPAC/Chemical Name: 2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R,6R,11R)-

InChi Key: HEYXXBUDMDVUNQ-CEWLAPEOSA-N

InChi Code: InChI=1S/C21H27NO2/c1-3-18-20-11-16-5-6-17(23)12-19(16)21(18,4-2)8-9-22(20)13-15-7-10-24-14-15/h5-7,10,12,14,18,20,23H,3-4,8-9,11,13H2,1-2H3/t18-,20+,21+/m0/s1

SMILES Code: OC1=CC=C2C([C@]3(CC)CCN(CC4=COC=C4)[C@]([C@@H]3CC)([H])C2)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 325.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bansinath M, Ramabadran K, Turndorf H, Puig MM. Effects of the benzomorphan kappa-opiate, MR 2266 and its (+) enantiomer MR 2267, on thermonociceptive reactions in different strains of mice. Neurosci Lett. 1990 Sep 4;117(1-2):212-7. doi: 10.1016/0304-3940(90)90146-z. PMID: 1963214.


2: Bauer U, Nakazi M, Kathmann M, Göthert M, Schlicker E. The stereoselective kappa-opioid receptor antagonist Mr 2266 does not exhibit stereoselectivity as an antagonist at the orphan opioid (ORL1) receptor. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):17-20. doi: 10.1007/pl00005317. PMID: 9933145.


3: Sandi C, Borrell J, Guaza C. Effects of the kappa opioid receptor antagonist MR-2266-BS on the acquisition of ethanol preference. Life Sci. 1990;46(16):1119-29. doi: 10.1016/0024-3205(90)90448-z. PMID: 2160572.


4: Frey HH. Effect of mu- and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR 2266. Pharmacol Toxicol. 1988 Mar;62(3):150-4. doi: 10.1111/j.1600-0773.1988.tb01863.x. PMID: 2836842.


5: Xu RK, Chen L, Li H, Yang SJ, Huang XY. [Effects of kappa-opiate receptor antagonist MR-2266-BS on ACTH and prolactin release]. Sheng Li Xue Bao. 1989 Aug;41(4):395-401. Chinese. PMID: 2557673.


6: Nabeshima T, Hiramatsu M, Kameyama T. Phencyclidine-induced stereotyped behaviors after injection of ethylketocyclazocine, Mr 2266 and naltrexone in rats. Brain Res. 1986 Jul 23;378(2):234-9. doi: 10.1016/0006-8993(86)90926-1. PMID: 3015356.


7: Ramabadran K, Bansinath M, Turndorf H, Puig MM. Effects of naloxone and Mr 2266 on thermonociceptive reactions in diabetic mice. NIDA Res Monogr. 1989;95:528-9. PMID: 2561849.


8: Laorden ML, Carrillo E, Puig MM. Prevention of hyperthermia-induced convulsions in immature rat by MR-2266, a kappa antagonist. Methods Find Exp Clin Pharmacol. 1991 Nov;13(9):605-8. PMID: 1686291.


9: Sandrini M, Romualdi P, Vitale G, Morelli G, Capobianco A, Pini LA, Candeletti S. The effect of a paracetamol and morphine combination on dynorphin A levels in the rat brain. Biochem Pharmacol. 2001 Jun 1;61(11):1409-16. doi: 10.1016/s0006-2952(01)00623-2. PMID: 11331077.


10: Prokudina ES, Maslov LN, Naryzhnaya NV, Tsibulnikov SY, Lishmanov YB, Madias JE, Oeltgen PR. Cardioprotective properties of opioid receptor agonists in rats with stress-induced cardiac injury. Physiol Res. 2019 Jun 30;68(3):375-384. doi: 10.33549/physiolres.933946. Epub 2019 Mar 22. PMID: 30904005.


11: Sandrini M, Romualdi P, Capobianco A, Vitale G, Morelli G, Pini LA, Candeletti S. The effect of paracetamol on nociception and dynorphin A levels in the rat brain. Neuropeptides. 2001 Apr;35(2):110-6. doi: 10.1054/npep.2001.0852. PMID: 11384206.


12: Rabkin SW. Endogenous kappa opioids mediate the action of brain angiotensin II to increase blood pressure. Neuropeptides. 2007 Dec;41(6):411-9. doi: 10.1016/j.npep.2007.09.003. Epub 2007 Nov 5. PMID: 17980907.


13: Jackisch R, Geppert M, Illes P. Characterization of opioid receptors modulating noradrenaline release in the hippocampus of the rabbit. J Neurochem. 1986 Jun;46(6):1802-10. doi: 10.1111/j.1471-4159.1986.tb08499.x. PMID: 2871130.


14: Vonvoigtlander PF, Lahti RA, Ludens JH. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther. 1983 Jan;224(1):7-12. PMID: 6129321.


15: Radulović J, Janković BD. Opposing activities of brain opioid receptors in the regulation of humoral and cell-mediated immune responses in the rat. Brain Res. 1994 Oct 24;661(1-2):189-95. doi: 10.1016/0006-8993(94)91196-7. PMID: 7834369.


16: Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol. 2004 Jan;65(1):2-11. doi: 10.1124/mol.65.1.2. PMID: 14722230.


17: Bhargava HN, Kremer EK, Gibbons MO, Philips BJ, Driver JW, Chou M. Stereospecific effects of a kappa-opiate antagonist on the actions of morphine in morphine-tolerant rats. Eur J Pharmacol. 1989 Dec 7;173(2-3):159-64. doi: 10.1016/0014-2999(89)90513-x. PMID: 2560431.


18: Stockhaus K, Ensinger HA, Gaida W, Jennewein HM, Merz H. Mr 2033 CL--a novel non-morphine-like opioid analgesic. NIDA Res Monogr. 1983 Apr;43:144-9. PMID: 6135993.


19: Ben-Sreti MM, Sewell RD, Upton N. Some observations on the effects of enantiomers of two benzomorphan narcotic antagonists and atropine on analgesia, tremor and hypothermia produced by oxotremorine. Arch Int Pharmacodyn Ther. 1982 Apr;256(2):219-27. PMID: 7103612.


20: Oka T, Negishi K, Kajiwara M, Watanabe Y, Ishizuka Y, Matsumiya T. The choice of opiate receptor subtype by neo-endorphins. Eur J Pharmacol. 1982 Apr 23;79(3-4):301-5. doi: 10.1016/0014-2999(82)90636-7. PMID: 6284522.